Under the agreement, LabCorp will offer clinical pathology testing, including cytology and cytology-related molecular testing, at Mount Sinai clinical outreach laboratories. Through the deal, LabCorp will also acquire seven of Mount Sinai’s patient service centers.
The transaction is expected to close in the first quarter of 2017. The financial terms of the agreement have not yet been disclosed.
More articles on transactions and valuations:
Little Company of Mary Hospital explores affiliation opportunities
Penn State College of Medicine, Summit Health forge academic partnership
UMass Memorial Medical Center to join Dana-Farber Cancer Care Collaborative
